Exactus, Inc. (EXDI) — AI 股票分析

Exactus, Inc. specializes in producing and supplying hemp-derived ingredients and feminized hemp genetics, catering to the cosmetic, wellness, and pharmaceutical sectors. As a subsidiary of Ceed2Med, LLC, the company operates in the evolving cannabinoid market, offering a range of specialty ingredients and white-label products.

Key Facts: Sector: Healthcare

公司概况

概要：

Exactus, Inc., a subsidiary of Ceed2Med, LLC, focuses on the production and supply of hemp-derived ingredients and feminized hemp genetics. Targeting the cosmetic, wellness, and pharmaceutical industries, the company offers specialty cannabinoid products and white-label services, positioning itself within the burgeoning hemp market amidst evolving regulations and increasing competition.

EXDI是做什么的？

Exactus, Inc., based in Delray Beach, Florida, specializes in the production and supply of hemp-derived ingredients and feminized hemp genetics. As a subsidiary of Ceed2Med, LLC, the company focuses on providing cannabidiol (CBD) feminized genetics, high cannabigerol (CBG) feminized genetics, hemp-derived specialty ingredients, and white-label products. These products cater to a diverse range of industries, including cosmetic, wellness, food, beverage, pharmaceutical, and pet sectors. Exactus offers a comprehensive suite of specialty ingredients, including CBD, CBG, CBN, and CBC isolates, as well as CBD and CBG distillates. The company also provides CBD water-soluble solutions, CBD and CBG biomass, CBD and CBG flowers, and CBD crude oil. In addition to these ingredients, Exactus offers custom manufactured specialty cannabinoid products, such as skincare products, pain creams, tinctures, bath bombs, soft gels, balms, pet products, and supplements. The company's business model is centered around supplying high-quality hemp-derived products to businesses that incorporate these ingredients into their own consumer offerings. By focusing on both raw materials and finished white-label products, Exactus aims to serve a wide spectrum of needs within the cannabinoid market. The company operates within a rapidly evolving regulatory landscape, requiring constant adaptation to compliance standards and market demands.

EXDI的投资论点是什么？

Exactus, Inc. presents a high-risk, high-reward investment opportunity within the volatile hemp-derived products market. The company's negative profit margin of -402.2% and gross margin of -100.0% indicate significant challenges in achieving profitability. Growth catalysts include expansion into new product lines and increased market penetration within the cosmetic and pharmaceutical sectors. However, the company's OTC listing and high beta of 4.32 reflect substantial market risk and volatility. The investment thesis hinges on Exactus's ability to scale production efficiently, navigate regulatory hurdles, and establish a sustainable competitive advantage in a rapidly evolving industry. The company's future success depends on effectively managing costs and capitalizing on the growing demand for hemp-derived products.

EXDI在哪个行业运营？

Exactus, Inc. operates within the rapidly expanding, yet highly competitive, hemp-derived products market. This market includes CBD, CBG, and other cannabinoid-based products, catering to the cosmetic, wellness, and pharmaceutical industries. The industry is characterized by evolving regulations, increasing consumer demand, and a fragmented competitive landscape. Companies like Acreage Holdings (ACRDF), and Columbia Care (CLSH) also compete in this space, focusing on various aspects of cannabis and hemp production. The market is projected to continue growing, driven by increasing acceptance of cannabinoid products and ongoing research into their potential health benefits. However, regulatory uncertainty and intense competition pose significant challenges for companies like Exactus.

Drug Manufacturers - Specialty & Generic

Healthcare

EXDI有哪些增长机遇？

Expansion into New Product Lines: Exactus can capitalize on the growing demand for specialized cannabinoid products by expanding its product line to include novel formulations and delivery methods. This includes developing advanced skincare products, pharmaceutical-grade cannabinoid formulations, and innovative wellness products. The market for specialized cannabinoid products is projected to reach $5 billion by 2028, offering a significant growth opportunity for Exactus if they can innovate and capture market share.
Increased Market Penetration in Cosmetic Sector: The cosmetic industry represents a significant growth opportunity for Exactus, with increasing demand for CBD and other cannabinoid-infused skincare and beauty products. By forging partnerships with established cosmetic brands and developing proprietary formulations, Exactus can expand its market presence in this sector. The global CBD skincare market is expected to reach $3.48 billion by 2029, presenting a substantial opportunity for Exactus to increase revenue and market share.
Strategic Partnerships with Pharmaceutical Companies: Exactus can pursue strategic partnerships with pharmaceutical companies to develop cannabinoid-based therapeutics and pharmaceutical products. This includes collaborating on research and development efforts, supplying high-quality cannabinoid ingredients, and co-marketing pharmaceutical products. The pharmaceutical cannabinoid market is projected to grow to $2.8 billion by 2028, offering a lucrative opportunity for Exactus to diversify its revenue streams and establish a presence in the pharmaceutical sector.
White-Label Product Expansion: Exactus can further expand its white-label product offerings to cater to the growing demand from brands seeking to enter the cannabinoid market without investing in their own production facilities. This includes offering a comprehensive suite of white-label products, such as tinctures, capsules, topicals, and edibles, with customizable formulations and branding options. The white-label cannabinoid market is expected to reach $1.5 billion by 2027, providing a significant growth opportunity for Exactus to increase its customer base and revenue.
International Market Expansion: Exactus can explore opportunities to expand its operations into international markets, particularly in Europe and Asia, where the demand for CBD and other cannabinoid products is growing rapidly. This includes establishing distribution partnerships, setting up local production facilities, and adapting its product offerings to meet the specific regulatory requirements and consumer preferences of each market. The international cannabinoid market is projected to reach $18 billion by 2028, offering a substantial growth opportunity for Exactus to diversify its revenue streams and expand its global footprint.

Negative Profit Margin of -402.2% indicates significant challenges in achieving profitability.
Negative Gross Margin of -100.0% suggests high production costs relative to revenue.
Beta of 4.32 indicates high volatility compared to the overall market.
Operates in the rapidly evolving and highly competitive hemp-derived products market.
Subsidiary of Ceed2Med, LLC, providing a degree of financial backing and operational support.

EXDI提供哪些产品和服务？

Produces and supplies hemp-derived ingredients.
Offers feminized hemp genetics.
Provides cannabidiol (CBD) feminized genetics.
Supplies high cannabigerol (CBG) feminized genetics.
Offers hemp-derived specialty ingredients like CBD, CBG, CBN, and CBC isolates.
Provides white-label products to various industries including cosmetic, wellness, and pharmaceutical.

EXDI如何赚钱？

Sells hemp-derived ingredients to cosmetic, wellness, and pharmaceutical companies.
Offers feminized hemp genetics to growers.
Provides white-label manufacturing services for cannabinoid products.
Generates revenue through the sale of specialty cannabinoid ingredients and finished products.

Cosmetic companies using CBD and other cannabinoids in skincare products.
Wellness companies incorporating hemp-derived ingredients into health and wellness products.
Pharmaceutical companies developing cannabinoid-based therapeutics.
Food and beverage companies adding CBD to their products.
Pet product companies creating CBD-infused pet products.

Proprietary feminized hemp genetics for high cannabinoid yields.
Established relationships with ingredient suppliers and manufacturers.
Expertise in cannabinoid extraction and formulation.
White-label manufacturing capabilities offering customized product solutions.

什么因素可能推动EXDI股价上涨？

Upcoming: Potential regulatory changes in the hemp-derived products market could create new opportunities or challenges.
Ongoing: Increasing consumer demand for CBD and other cannabinoid-infused products.
Ongoing: Expansion of white-label manufacturing capabilities to attract new customers.
Upcoming: Potential partnerships with established cosmetic or pharmaceutical brands.
Ongoing: Development of new and innovative cannabinoid formulations.

EXDI的主要风险是什么？

Ongoing: Intense competition in the hemp-derived products market.
Potential: Regulatory uncertainty and compliance challenges.
Potential: Fluctuations in commodity prices for hemp-derived ingredients.
Potential: Changes in consumer preferences and market trends.
Ongoing: Negative profit margin and gross margin indicating financial instability.

EXDI的核心优势是什么？

Specialized in hemp-derived ingredients and feminized hemp genetics.
Offers a range of cannabinoid products including CBD, CBG, CBN, and CBC isolates.
Provides white-label manufacturing services.
Serves diverse industries including cosmetic, wellness, and pharmaceutical.

EXDI的劣势是什么？

Negative profit margin and gross margin.
High beta indicating high volatility.
OTC listing reflects higher risk and lower liquidity.
Dependence on evolving regulatory landscape.

EXDI有哪些机遇？

Expansion into new product lines and markets.
Strategic partnerships with established brands.
Increased demand for cannabinoid-infused products.
Growth in the cosmetic and pharmaceutical sectors.

EXDI面临哪些威胁？

Intense competition in the hemp-derived products market.
Regulatory uncertainty and compliance challenges.
Fluctuations in commodity prices.
Potential changes in consumer preferences.

EXDI的竞争对手是谁？

Acreage Holdings, Inc. — Focuses on cannabis cultivation, processing, and dispensing. — (ACRDF)
BevCanna Enterprises Inc. — Develops and manufactures cannabinoid-infused beverages and products. — (BCBCF)
China Xiangtai Food Co., Ltd. — Diversified company with interests in food and cannabis sectors. — (CHNC)
Columbia Care Inc. — Operates medical cannabis dispensaries and cultivation facilities. — (CLSH)
4Front Ventures Corp. — Focuses on cannabis retail and brand development. — (FLWPF)

Company Profile

CEO: Alvaro Daniel Alberttis
Headquarters: Delray Beach, US
Founded: 2015

AI Insight

AI analysis pending for EXDI

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Exactus, Inc. do?

Exactus, Inc. specializes in the production and supply of hemp-derived ingredients and feminized hemp genetics. The company provides cannabidiol (CBD) feminized genetics, high cannabigerol (CBG) feminized genetics, hemp-derived specialty ingredients, and white-label products to the cosmetic, wellness, food, beverage, pharmaceutical, and pet industries. Their offerings include CBD, CBG, CBN, and CBC isolates, distillates, water-soluble solutions, biomass, flowers, and crude oil, as well as custom manufactured specialty cannabinoid products.

What do analysts say about EXDI stock?

As of 2026-03-17, formal analyst ratings for Exactus, Inc. (EXDI) are not available, likely due to its OTC listing and smaller market capitalization. Key valuation metrics include a negative P/E ratio of -0.30, reflecting current losses. Investors should focus on monitoring revenue growth, cost management, and progress towards profitability. The company's growth potential hinges on its ability to capitalize on the expanding market for hemp-derived products while navigating regulatory challenges and intense competition.

What are the main risks for EXDI?

Exactus, Inc. faces several key risks, including intense competition in the rapidly evolving hemp-derived products market. Regulatory uncertainty and compliance challenges pose significant threats. The company's negative profit and gross margins highlight financial instability. Fluctuations in commodity prices for hemp-derived ingredients and potential shifts in consumer preferences also present risks. The OTC listing adds further risk due to limited regulatory oversight and potential liquidity issues.